CLIMB BIO, INC. (CLYM) Free cash flow
- Free cash flow · 12 months (USD): Value $-53.07M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-53.07M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-52.70M − $369.00K ≈ $-53.07M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-52.70M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.91× | Operating cash flow / net income. Period ending 2026-06-30. $-52.70M ÷ $-57.62M ≈ 0.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -52.70M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 369.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -53.07M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -57.62M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-53.07M | (m) | $-52.70M | $369.00K | (m) | (m) | (m) | $-57.62M | (m) | (m) | (m) | 0.91× |
| 2026-03-31 | (m) | (m) | $-53.30M | (m) | (m) | (m) | (m) | $-52.79M | (m) | (m) | (m) | 1.01× |
| 2025-12-31 | $-54.54M | (m) | $-54.36M | $186.00K | (m) | (m) | (m) | $-59.85M | (m) | (m) | (m) | 0.91× |
| 2025-09-30 | (m) | (m) | $-44.24M | (m) | (m) | (m) | (m) | $-50.75M | (m) | (m) | (m) | 0.87× |
| 2025-06-30 | (m) | (m) | $-39.66M | (m) | (m) | (m) | (m) | $-46.76M | (m) | (m) | (m) | 0.85× |
| 2025-03-31 | (m) | (m) | $-29.18M | (m) | (m) | (m) | (m) | $-92.98M | (m) | (m) | (m) | 0.31× |
| 2024-12-31 | (m) | (m) | $-15.56M | (m) | (m) | (m) | (m) | $-73.90M | (m) | (m) | (m) | 0.21× |
| 2024-09-30 | (m) | (m) | $-10.99M | (m) | (m) | (m) | (m) | $-69.12M | (m) | (m) | (m) | 0.16× |
| 2024-06-30 | (m) | (m) | $57.00K | (m) | (m) | (m) | (m) | $-64.19M | (m) | (m) | (m) | -0.00× |
| 2024-03-31 | (m) | (m) | $-7.24M | (m) | (m) | (m) | (m) | $-14.53M | (m) | (m) | (m) | 0.50× |
| 2023-12-31 | (m) | (m) | $-20.60M | (m) | (m) | (m) | (m) | $-35.12M | (m) | (m) | (m) | 0.59× |
| 2023-09-30 | (m) | (m) | $-28.10M | (m) | (m) | (m) | (m) | $-39.24M | (m) | (m) | (m) | 0.72× |
| 2023-06-30 | (m) | (m) | $-35.77M | (m) | (m) | (m) | (m) | $-44.95M | (m) | (m) | (m) | 0.80× |
| 2023-03-31 | (m) | (m) | $-41.77M | (m) | (m) | (m) | (m) | $-54.33M | (m) | (m) | (m) | 0.77× |
| 2022-12-31 | (m) | (m) | $-37.37M | (m) | (m) | (m) | (m) | $-45.24M | (m) | (m) | (m) | 0.83× |
| 2022-09-30 | (m) | (m) | $-36.80M | (m) | (m) | (m) | (m) | $-48.03M | (m) | (m) | (m) | 0.77× |
| 2022-06-30 | (m) | (m) | $-45.60M | (m) | (m) | (m) | (m) | $-47.96M | (m) | (m) | (m) | 0.95× |
| 2022-03-31 | (m) | (m) | $-40.11M | (m) | (m) | (m) | (m) | $-42.08M | (m) | (m) | (m) | 0.95× |
| 2021-12-31 | (m) | (m) | $-36.07M | (m) | (m) | (m) | (m) | $-47.48M | (m) | (m) | (m) | 0.76× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $-14.10M | (m) | (m) | (m) | (m) | $-20.67M | (m) | (m) | (m) | 0.68× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |